



ReSoK | RESPIRATORY SOCIETY OF KENYA

**PATS & ReSoK Congress
7-10 June 2023**

PROGRAMME




SAROVA WHITESANDS
BEACH RESORT & SPA
MOMBASA



Centre for Health Solutions - Kenya

Preferred Partner for Health Solutions



WHO WE ARE

CHS is a local not-for-profit organization. We understand the local context and implement evidence solutions and interventions to existing and emerging public health needs



WHAT WE DO

We reach communities across Kenya through the delivery of HIV and TB services while strengthening all the core components of the health systems; including supportive functions such as laboratory and pharmacy systems, (M&E), human resources for health, and health care financing.



OUR IMPACT

Since 2010, we have reached over 7,000,000 Kenyans with HIV and TB health services, we continue to change lives by consistently focusing on the delivery of quality services.



Centre for Health Solutions - Kenya

Preferred Partner for Health Solutions

OUR WORK IN TB CONTROL



Improve access to high quality, patient-centered TB, DR-TB and TB/HIV services



Prevent TB transmission and disease progression



Strengthen TB service delivery platforms



Accelerate research and innovation



Improve TB case finding



In collaboration with Kenya's National Tuberculosis, Leprosy, and Lung Disease Program (NTLD-P), Tuberculosis Accelerated Response and Care II (TB ARC II) seeks to reduce the incidence, and TB related morbidity, and mortality in Kenya. It is funded by the United States Agency for International Development (USAID)



Welcome to the PATS & ReSoK Congress 2023

Dear Colleagues and friends,

I warmly welcome you to the 3rd Biennial Pan African Thoracic Society Congress. It is exciting to meet everyone face to face again after a long time. Our theme this year, "The African Environment and Lung Health", explores the effects of physical and social environment on lung health in the African and global contexts. Africa remains overburdened with respiratory disease and addressing this requires multifaceted, multidisciplinary approaches.

The program will feature distinguished international speakers and experts in respiratory health and thoracic surgery and it has been designed to cover topics related to the spectrum of respiratory diseases, equity of access to medicines, usage of international guidelines and other topics that will help us to jointly explore context-specific, sustainable solutions to improving lung health. Some workshops to anticipate this year include thoracic ultrasound, pulmonary rehabilitation, air quality monitoring, and dissemination sessions from recent exciting studies. We also have many clinical cases and abstracts highlighting some of the excellent researches conducted in Africa and beyond.

This conference provides a fantastic opportunity to share knowledge, build connections and contribute to developing capacity and tackling global health challenges. Following the success of the innovative Congress App introduced at our last conference, this conference will feature upgrades. We encourage participants to also join the conversation online by joining our Facebook group (@panafricanthoracicsociety) and connecting with us on Twitter (@patscommunity).

Hosted in the beautiful coastal city of Mombasa, Kenya, this year's conference promises to be exciting, and we encourage participants to take this opportunity to enjoy the many tourist attractions the city offers.

I am most grateful to the planning committee for their contributions to designing and organizing this educative and informative conference. It is because of their unwavering commitment to executing the vision of the Pan African Thoracic Society to unite African Thoracic societies, lead advocacy efforts, and share resources to improve the standards of practice in Africa, that this year's conference is possible. I am very grateful to our co-hosts, the Respiratory Society of Kenya, who share this vision and commitment. Sincere thanks also goes to the American Thoracic Society, British Thoracic Society, and European Respiratory Society for their partnership.

I am confident that this conference will be most enjoyable and look forward to your participation.

Welcome!
Obianuju Ozoh
Congress Chair





Welcome to the PATS & ReSoK Congress 2023

Message from The President of Pan African Thoracic Society

I wish to extend a warm welcome to all delegates and participants to the PATS & RESOK Congress 2023. This conference, taking place in Mombasa, the Kenyan coastal city that exudes beauty and unparalleled hospitality, brings together African and international scholars, researchers, clinicians, nurses, laboratory specialists, public health practitioners, lung health advocates and other health care professionals to learn, disseminate research findings, share experiences, network and to raise attention on the status of the lung health in Africa so as to shape the future.

The congress theme "The African Environment and Lung Health" has been carefully chosen to align with identified key priorities for strengthening lung health in Africa and indeed globally. These include air pollution and climate change, as well as social factors such as poverty, overcrowding, and displacement. We have put together a stimulating programme featuring distinguished speakers exploring past, current, and future activities to promote lung health and will provide a platform to tackle together our major respiratory health challenges. The program includes topics on adult and pediatric respiratory health and thoracic surgery. Topics range from clinical care and disease burden, to risk factors, improving research and strengthening health systems within African low-resource settings. We have also included Skills building workshops namely thoracic ultrasound, pulmonary rehabilitation, air quality monitoring and other relevant topics.

I trust that delegates and participants to the 3rd Biennial Pan African Thoracic & Respiratory Society of Kenya Congress 2023 will greatly enjoy the conference and take the opportunity to explore and enjoy the natural pleasures of the Kenyan coast.

Karibuni

Prof. Joseph A Aluoch FRCP, EBS
President PATS, Nairobi





Welcome to the PATS & ReSoK Congress 2023

Welcome message from ReSoK President

The Respiratory Society of Kenya is greatly honoured and privileged to host the third PATS Conference and welcomes you all to the historical City of Mombasa which is a cauldron of different cultures and languages. Our vision in the Respiratory Society of Kenya is to be the leading reference organization providing world-class lung health solutions within our borders and beyond. We engage in partnerships with governmental agencies, international organisations, and Private entities to engage in advocacy, conducting value-adding research, promoting innovation and education in our communities, and training of healthcare providers. We work with and support different entities that seek to primarily enhance lung health and public health in general. We believe this conference, which is so aptly themed, will contribute in no small way towards our mission. We look forwards to forging closer ties with PATS and other member Societies towards our shared goals and aspirations, including and not limited to PATS-MECOR, Respiratory Specialist, and other Allied support training Programs, and initiatives that improve Lung Health, in general.

The World Health Organization estimates that 99% of the global population inhales air that is polluted beyond its guidelines, and we in low- and middle-income countries have the highest exposure. A healthy Environment is central to a healthy society, and as Respiratory care professionals, we, unfortunately, bear the brunt of diseases that directly result from an unhealthy environment. Poor air quality, pollution of different elements, and poor hygiene, in general, continue to drive morbidity and mortality in our world, and PATS must pool our collective minds, harness our collective efforts to influence policy, identify and provide pertinent training and education programs, dictate research questions and synergise multilateral resources that all work towards a healthier environment and a healthier society.

Like other coastal communities along the Indian Ocean, Mombasa has a lot to offer in history, culture, and entertainment and we hope that you shall find time to sample our eclectic cuisine, beautiful beaches and a lot more that Kenya has to offer.

Karibunisana!

Prof Jumaa Bwika
President - ReSoK



For risk reduction and symptom control in asthma...¹ The difference is SYMBICORT™

A GINA preferred controller¹

Regular ICS-LABA (budesonide/formoterol) maintenance treatment every day¹

Additional benefits of:

39 % reduction in exacerbations vs. fluticasone/salmeterol²

7 x improvement in asthma control days vs. baseline²

Symptom relief as fast as a SABA³



SYMBICORT™
Maintenance Therapy
in Asthma^{4,5,6}



Every morning

1-2 inhalations



Every evening

1-2 inhalations

GINA – Global Initiative for Asthma; ICS – inhaled corticosteroid; LABA – long-acting beta-2 agonist; SABA – short-acting beta-2 agonist

References: 1. GINA. Pocket guide for asthma management and prevention. Updated 2020. Available from https://ginasthma.org/gina-reports/main-pocket-guide_2020_04_03-final-wms/. 2. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. *Int J Clin Pract* 2007;61(5):725-736. 3. Seberova E, Andersson A, Oxis® (formoterol given by Turbuhaler®) shows as rapid an onset of action as salbutamol given by pMDI. *Respiratory Medicine* 2000;94:607-611. 4. Symbicort™ Turbuhaler™ 80/4.5 standard export leaflet, February 2017. Symbicort™ Turbuhaler™ 160/4.5 standard export leaflet, February 2017. Symbicort™ Turbuhaler™ 320/9 Inhaler standard export leaflet, November 2008.

Symbicort™ Turbuhaler™ 80/4.5 µg/dose (Inhalation powder). Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide 80 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation. Symbicort™ Turbuhaler™ 80/4.5 micrograms/inhalation delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler™ monoproducts, i.e. budesonide 100 micrograms/inhalation (metered dose) and formoterol 6 micrograms/inhalation (metered dose) alternatively labelled as 4.5 micrograms/inhalation (delivered dose). Excipient: Lactose monohydrate 810 micrograms per dose. **PHARMACEUTICAL FORM:** Inhalation powder. **THERAPEUTIC INDICATION:** Symbicort™ Turbuhaler™ is indicated in adults, adolescents, and children aged 6 years and older for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta₂-agonist) is appropriate; patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta₂-agonists, or patients already adequately controlled on both inhaled corticosteroids and long acting beta₂-agonists. Note: Symbicort™ Turbuhaler™ 80/4.5 micrograms/inhalation is not appropriate in patients with severe asthma. **Symbicort™ Turbuhaler™ 160/4.5 µg/dose (Inhalation powder).** Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide 160 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation. Symbicort™ Turbuhaler™ 160/4.5 micrograms/inhalation delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler™ monoproducts, i.e. budesonide 200 micrograms/inhalation (metered dose) and formoterol 6 micrograms/inhalation (metered dose) alternatively labelled as 4.5 micrograms/inhalation (delivered dose). Excipient: Lactose monohydrate 730 micrograms per dose. **PHARMACEUTICAL FORM:** Inhalation powder. **THERAPEUTIC INDICATIONS:** Asthma. Symbicort™ Turbuhaler™ is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta₂-agonist) is appropriate; patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta₂-agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting beta₂-agonists. COPD. Symbicort™ Turbuhaler™ is indicated in adults, and 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV₁) < 70 % predicted normal, (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy. **Symbicort™ Turbuhaler™ 320/9 µg/dose (Inhalation powder).** Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide 320 micrograms/inhalation and formoterol fumarate dihydrate 9 micrograms/inhalation. Symbicort™ Turbuhaler™ 320/9 micrograms/inhalation delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler™ monoproducts, i.e. budesonide 400 micrograms/inhalation (metered dose) and formoterol 12 micrograms/inhalation (metered dose) alternatively labelled as 9 micrograms/inhalation (delivered dose). **PHARMACEUTICAL FORM:** Inhalation powder. **THERAPEUTIC INDICATION:** Asthma. Symbicort™ Turbuhaler™ is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta₂-agonist) is appropriate; patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta₂-agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting beta₂-agonists. COPD. Symptomatic treatment of patients with severe COPD (FEV₁ < 50 % predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. For full prescribing information refer to the Standard Export Leaflet approved by the medicines regulatory authority. Symbicort™ and Turbuhaler™ are trademarks of the AstraZeneca group of companies.

AstraZeneca Pharmaceuticals (Pty) Ltd. Reg. No. 1992/005854/07, Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, Private Bag X23, Bryanston, 2021. Tel: +27 (0) 11 797-6000. Fax: +27 (0) 11 797-6001. www.astrazeneca.com. Expiry Date: May 2024. Activity ID: X5-2832.

Symbicort™
budesonide/formoterol



Programme

WEDNESDAY 7 JUNE 2023		
07:00	Registration for pre-congress workshops open	Tent
Pre-congress Workshops		
08:30-12:30	Dissemination Meeting 1 - IMPALA Dissemination <i>Venue: Baraza 2</i>	Wanjiku Kagima (Kenya)
13:30-16:30	Dissemination Meeting 2 - TUPUMUE Dissemination <i>Venue: Baraza 2</i>	Graham Devereux (UK)
08:00-16:30	Skills Building Workshop 1 - Spirometry <i>Venue: Baraza 1</i>	Lindsay Zurba (South Africa)
13:30-16:30	Skills Building Workshop 2 - Pulmonary Rehabilitation <i>Venue: Baraza Sebule</i>	Sally Singh (UK)
08:00-16:30	Skills Building Workshop 3 - Video Assisted Thoracoscopy <i>Off Site</i>	Nabil Khan (Germany) & N.S. Rodriguez (UAE)
08:00-16:30	Skills Building Workshop 4 - Thoracic Ultrasound <i>Venue: Baraza 3</i>	Sheila Masheti (Kenya)
17:30-18:00	Opening Ceremony MC: Lorraine Mugambi-Nyaboga (Kenya)	Venue: Johari 2-A
	Welcome Address ReSoK Chairperson	Jumaa Bwika (Kenya)
	Welcome Address PATS Chairperson	Joseph Aluoch (Kenya)
	Welcome Address Congress Chair	Obianuju Ozoh (Nigeria)
	Message from the National Medical Association	Simon Kigonda (Kenya)
	Vote of thanks	Jeremiah Chakaya (Kenya)
18:00-19:00	Plenary 1: Climate change and lung health Chair: Jeremiah Chakaya (Kenya) & Refiloe Masekela (South Africa)	Venue: Johari 2-A
18:00-18:30	Climate change and lung health	Arzu Yorgancioglu (Türkiye)
18:30-19:00	The Social environment and lung health	Martha Chinouya (UK)
19:00	Registration for full congress opens	
19:00	Cocktail Function and organized entertainment	
THURSDAY 8 JUNE 2023		
08:00	Registration & CPD Scanning opens	Tent
08:30-10:00	Plenary 2: Burden of Respiratory disease in Africa Chairs: Lisa Maleche Obimbo (Kenya) & Evans Amukoye (Kenya)	Venue: Johari 2-A
08:30-08:50	Trends in respiratory disease burden in Africa	Davies Adeloje (Nigeria/UK)
08:50-09:20	SABINA study presentation (AstraZeneca sponsored)	Jeremiah Chakaya (Kenya)
09:20-09:40	Impact of tobacco and tobacco products on Lung health	Andy Bush (UK)
09:40-10:00	Air pollution and lung cancer	Bertrand Mbatchou (Cameroon)
10:00-10:30	TEA/COFFEE	
10:30-12:30	Adult Track 1: Optimizing treatment of chronic airway disease in Africa Chairs: George Nyale (Kenya) & Wanjiku Kagima (Kenya)	Venue: Johari
10:30-10:50	Severe asthma in Africa: is personalized care possible?	Bruce Kirenga (Uganda)
10:50-11:10	Coping with the burden of COPD in sub-Saharan Africa	Jumaa Bwika (Kenya)
11:10-11:30	Managing asthma and COPD in resource limited settings	Kevin Mortimer (UK)
11.30-12:00	Challenges of asthma diagnosis in the African set up Oral Abstract Presentations:	Jackson Atina
12:00-12:10	Characteristics and phenotypes of a COPD patient cohort in Uganda	Patricia Alupo (Uganda)





Programme

- 12:10-12:20 Allergic asthma phenotype among Nigerians: towards personalized care Ogochukwu Eketé (Nigeria)
- 12:20-12:30 "Asthma is a bully disease" – Experiences of patients with chronic lung diseases when negotiating the health system in Cape Town Metro, South Africa Marie Stolbrink (South Africa)

10:30-12:30 Paediatric Track 1: Asthma and Allergies in Children Chairs: Priya Bowry (Kenya) & Joy Eze (Nigeria) Venue: Baraza 2&3

- 10:30-11:00 Asthma in African children – is atopy important? Adaeze Ayuk (Nigeria)
- 11:00-11:30 Severe asthma phenotypes and management Andy Bush (UK)
- 11:30-12:00 The challenge of adopting and adapting to the new GINA guidelines in Africa Refiloe Masekela (South Africa)
- Oral Abstract Presentations:**
- 12:00-12:10 Latent Trajectory Modelling of longitudinal clinical data: An application to birth cohort study in the Western Region of The Gambia Nicola Marozva (South Africa)
- 12:10-12:20 Preterm birth, birth weight, infant weight gain and their associations with childhood asthma and lung function: a study in Kenya Graham Deveraux (UK)
- 12:20-12:30 Tupumue: a study of asthma, lung function and air pollution exposures in schoolchildren in an informal (slum) settlement and a more affluent area of Nairobi Helen Meme (Kenya)

10:30-12:30 Thoracic Surgery Track 1: VATS I Chairs: N.S. Rodriguez (UAE) & N. Khan (Germany) Venue: Forodhahi

- 10:30-11:00 Evolution of VATS and RATS: My Journey Diego Gonzalez (Spain) [Virtual]
- 11:00-11:25 Evolution of VATS in Africa Souheil Boubia (Morocco)
- 11:25-11:50 How to Start a VATS Program Alan Sihoe (HK) [Virtual]
- 11:50-12:15 Surviving a minimally invasive program in a developing country Hussein Elkhayat (Egypt)
- 12:15-12:30 Panel discussion

12:30-13:15 LUNCH Venue: Pavilion Restaurant

13:15-13:45 LUNCH & POSTER VIEWING Venue: Johari 2-B

- (P201) Using creative activities to sensitise communities in Nairobi to lung health and air pollution research
Reviewer: Heather Zar
- (P202) Time to appropriate care-seeking for Covid – 19 symptoms
Reviewer: Amsalu Binegdie
- (P203) The availability, cost, and affordability of essential medicines for asthma and COPD in low- and middle-income countries: A systematic review
Reviewer: Refiloe Masekela
- (P204) Treatment intervention strategies for asthma and chronic obstructive pulmonary disease in Malawi - economic evaluation based on a five-year population cohort
Reviewer: Amsalu Binegdie
- (P205) Surveillance of Common Respiratory Viruses in Senegal During the Covid-19 Pandemic: Focus on Respiratory Syncytial Virus (RSV)
Reviewer: Sandra Kwarteng Owusu
- (P206) Lower plasma nitric oxide and pulmonary function parameters in Nigerian children with sickle cell anaemia compared to non-sickle cell children
Reviewer: Sandra Kwarteng Owusu
- (P207) Malaria, COVID-19 and hyper-inflammation in a paediatric patient
Reviewer: Heather Zar
- Cindy M Gray
- Ekat Martin Herbas
- Marie Stolbrink
- Martin Njoroge
- Jallow Mamadou Malado
- Oyebimpe.A Adeniyi
- Anne Irungu





Programme

(P208) Prevalence and Determinants of Respiratory Symptoms Among Commercial Taxi Drivers in Douala Cameroon <i>Reviewer: Sean Semple</i>	Atongno Humphrey Ashu
(P209) Assessment Of Lung Function And Oxygen Saturation In Children With Sickle Cell Anaemia At Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi State, Nigeria <i>Reviewer: Sandra Kwarteng Owusu</i>	Nnenna Ugo Nweke
(P210) Evaluating a mobile health tool to guide management of acute respiratory illnesses in young children in Uganda <i>Reviewer: Refiloe Masekela</i>	Rebecca Nantanda
(P211) Spirometry reference values for healthy children and adolescents in Tanzania <i>Reviewer: Refiloe Masekela</i>	Julieth Lalashowi
(P212) The influence of maternal allergy or atopy on child wheezing and lung function at two years in a South African birth cohort study <i>Reviewer: Adaeze Ayuk</i>	Evelyn Ng'ang'a
(P213) Rare cause of Bilateral Vocal Cord Paralysis and Diaphragm Dysfunction <i>Reviewer: Adaeze Ayuk</i>	Sindiswa Makate
(P214) Indoor air pollution, knowledge of sources and Respiratory Symptoms among Women in Kano State <i>Reviewer: Sean Semple</i>	Aishat Shittu
(P215) Fortuitous Discovery of a Double Superior Vena Cava <i>Reviewer: Ivan Schewitz</i>	Gourti Mouad
(P216) Unusual Metastatic Sites for Lung Cancer: About 4 Cases <i>Reviewer: Ivan Schewitz</i>	Gourti Mouad
(P217) "We have a human right to breath fresh air": Health inequalities and the Social Determinants of Asthma <i>Reviewer: Heather Zar</i>	Martha Chinouya

13:45-15:15 Plenary 3: Transforming access to inhaled medicine in Africa
Chairs: Andy Bush (UK) & Jane Ongango **Venue: Johari 2-A**

13:45-14:10	Inhaled medicines for asthma and COPD: the current picture of availability and affordability	Kevin Mortimer (UK)
14:10-14:30	Inhaled medicines for asthma and COPD in sub-Saharan Africa: why are they not available and affordable?	Obianuju Ozoh (Nigeria)
14:30-14:50	Generating the evidence to inform strategies to improve access to inhaled medicines for asthma and COPD in sub-Saharan Africa	Refiloe Masekela (South Africa)
14:50-15:15	Global collaboration to catalyse action on improving access to inhaled medicines for asthma and COPD in sub-Saharan Africa	Shami Jayasooria (UK)

13:45-15:30 Thoracic Surgery Track 2: VATS II
Chairs: S. Boubia (Morocco) & H. Elkhayat (Egypt) **Venue: Forodhahi**

13:45-14:10	Uniportal VATS – Perimammary Approach	Norberto Santana Rodriguez (UAE)
14:10-14:35	Nuss Procedure for Pectus Excavatum	Ivan Schewitz (South Africa)
14:35-14:55	Subxiphoid Approach for Mediastinal Tumors	Nabil Khan (Germany)
14:55-15:15	VATS in the Paediatric Patient	Firas Abu Akar (Israel) [Virtual]
15:15-15:30	TEA/COFFEE	





Programme

15:30-17:00	Adult Track 2: Case and abstract presentations Chairs: Jumaa Bwika (Kenya) & Jared Mecha (Kenya)	Virtual
15:30-15:50	Pulmonary alveolar proteinosis and whole lung lavage in Kenya: a case report	Evans Onyango (Kenya)
15:50-16:10	Malignant pleural mesothelioma and environmental and occupational exposure to asbestos: a case report from Lubumbashi, DR Congo	Joseph Pyana Kitenge (Congo)
	<u>Oral Abstract Presentations:</u>	
16:10-16:20	Catastrophic health expenditure, social protection coverage, and financial coping strategies amongst adults with symptoms of chronic respiratory diseases in Kenya: a cross-sectional study	Stephen Mulupi (Kenya)
16:20-16:30	Going AGILE (Adapt, Grow, Innovate, Lean-in and Execute)	Cheryl Kerama (Kenya)
16:30-16:40	Assessment of Inhaler Technique Demonstration among Healthcare Workers in Port Harcourt, Nigeria	Chidiebere Chukwuma (Nigeria)
16:40-16:50	Chronic respiratory disease in adult out-patients in three African countries: a cross sectional study	Barbara Miheso (Kenya)
16:50-17:00	The Utility of Clinician-Performed Cardiopulmonary Ultrasound Assessment of the Acutely Breathless Patient: Breathlessness Early Detection with Ultrasound (BED-US) Study	Wanjiku Kagima (Kenya)
15:30-17:00	Paediatric Track 2: The life course and lung health in children Chairs: Lisa Maleche Obimbo (Kenya) & Sandra Kwarteng Owusu (Ghana)	Venue: Baraza 2&3
15:30-16:00	The impact of air pollution on child health	Joy Eze (Nigeria)
16:00-16:30	Lung function testing in children: can we improve on the current status	Diane Gray (South Africa)
16:30-17:00	The early life origins of chronic lung disease	Andy Bush (UK)
15:30-18:00	Thoracic Surgery Track 3: Trauma Chairs: N. Khan (Germany) & S. Boubia (Morocco)	Venue: Forodhahi
15:30-15:50	Thoracic Trauma – Chest Wall Packing	Norberto Santana Rodriguez (UAE)
15:50-16:10	Pros and Cons of Chest Wall Trauma Stabilisation	Jose Ribas M. Campos (Brazil) [Virtual]
16:10-16:30	Non-intubated VATS	Nabil Khan (Germany)
16:30-16:50	Antibiotic Prophylaxis After Thoracic Drainage: Systematic or Habitual Without Evidence?	Gourti Mouad (Morocco)
17:00-18:00	Thoracic surgery in Africa: The Way forward. Election of Surgeons committee	Ivan Schewitz (South Africa)
17:30-18:30	Evening Symposium (Qure.ai Sponsored)	
19:00	Speakers' Dinner	Joseph Aluoch (Kenya)
FRIDAY 9 JUNE 2023		
08:00	Registration & CPD Scanning opens	Tent
08:30-10:00	Plenary 4: Infections and Bronchiectasis in Africa Chairs: Warurua Mugo (Kenya) & Jumaa Bwika (Kenya)	Venue: Johari 2-A
08:30-09:00	Respiratory Syncytial virus infection: State of the art	Heather Zar (South Africa)
09:00-09:30	Bronchiectasis: State of the art	Amsalu Binegdie (Ethiopia)
09:30-10:00	Surgery for Bronchiectasis, an Overview	Norberto Santana Rodriguez (UAE)
10:00-10:30	TEA/COFFEE	





Programme

10:30-12:00	Adult Track 3: Pneumonia in Africa: lessons from COVID-19 Chairs: Waweru Munyi (Kenya)	Venue: Johari
10:30-11:00	Oxygen delivery in Africa: lessons from COVID-19 Oral Abstract Presentations:	Benjamin Wachira (Kenya)
11:00-11:10	Challenges in optimizing CASS procedures in a resource limited setup	Lenis Kalvin Njagi (Kenya)
11:10-11:20	Assessment and associated factors of respiratory health-related quality of life of drug susceptible and multi-drug resistant pulmonary tuberculosis survivors from two Nigerian centers	Jibril Mohammed (Nigeria)
11:20-11:30	Barriers to Accessing Successful Treatment of TB Infection Among Male Adolescents and Young Adults: A Political Economy Analysis in Kenya	Leyla Abdullahi (Kenya)
11:30-11:40	COVID-19 Outbreak and Containment among Healthcare workers in a Tertiary Hospital in Nigeria	Ifeoma Ude (Nigeria)
11:40-11:50	Laboratory Challenges in Conducting TB Prevalence Survey in Post -COVID pandemic Recovery Era: The Nairobi 2022 TB Prevalence Survey Experience	Erick Nyadimo (Kenya)
11:50-12:00	Implementing Of Active Case Finding Model The Case Of Oruba Nursing And Maternity Private Facility	Maren Akoth Aseno (Kenya)
10:30-12:40	Paediatric Track 3: Tuberculosis Chairs: Anne Lomole (Kenya) & Adaeze Ayuk (Nigeria)	Venue: Baraza 2&3
10:30-11:00	Post-TB lung disease in children	Sandra Kwarteng Owusu (Ghana)
11:00-11:30	Drug Resistant TB what's new	Moherndran Archary (South Africa)
11:30-12:00	New advances in TB diagnosis in children Oral Abstract Presentations:	Diana Marangu (Kenya)
12:00-12:10	Assessment of Factors that Affect Diagnosis and Management of Childhood Tuberculosis Among Healthcare Workers in Siaya County, Kenya	Felix Oloo (Kenya)
12:10-12:20	Lung function trajectories in South African children with pulmonary TB: a prospective study	Diane Gray (South Africa)
12:20-12:30	Chronic respiratory disease is common in HIV infected children and adolescents in long-term care in Nairobi, and is associated with air pollution exposure	Elizabeth Maleche-Obimbo (Kenya)
12:30-12:40	Quantifying personal exposure to air pollution among school children in Nairobi: measurement data from homes, schools and outside spaces	Sean Semple (UK)
10:30-12:30	Thoracic Surgery Track 4 Chairs: I. Schewitz (South Africa) & N. Khan (Germany)	Venue: Forodhahi
10:30-11:30	CT Radiology for the Surgeon: Low dose lung screening	Shane Dorfman (South Africa) [Virtual]
11:30-11:55	Management of Airway Complications	Norberto Santana Rodriguez (UAE)
11:55-12:20	Nightmares in Thoracic Surgery	Ivan Schewitz (South Africa)
12:20-12:45	Pectus Arcuatum or Foreign Body Extraction per UVATS	Nabil Khan (Germany)
12:45-13:15	LUNCH	Venue: Pavilion Restaurant
12:45-13:45	PATS AGM	
13:15-13:45	POSTER VIEWING (P301) Inf- γ and Il-2 Asses the Therapeutic Response in Anti-tuberculosis Patients at Jamot Hospital Yaounde, Cameroon <i>Reviewer: Evans Amukoye</i>	Venue: Johari 2-B Membangbi Alexandra Emmanuelle





Programme

(P302) Profile and factors associated with survival of patients that received physiotherapy during admission in the intensive care unit (ICU) in Kano <i>Reviewer: Wanjiku Kagima</i>	Jibril Mohammed
(P303) Impact of computer aided detection (CAD4tb) chest x-ray on TB case detection among people living with HIV (PLHIV) in Madiany Hospital <i>Reviewer: Lorraine Mugambi</i>	Felix Oloo
(P304) Pattern, correlates of respiratory symptoms and Lung function among Shisha Smokers in Kano, Nigeria <i>Reviewer: Betrand Mbatchou</i>	Aishat Shittu
(P305) Assessment of the effect of Computer Aided Detection (CAD4TB) enabled chest x-ray (CXR) on screening for Tuberculosis cases in Mathare North Health Centre <i>Reviewer: Lorraine Mugambi</i>	Caroline Macharia
(P306) How overcrowding affects the transmission of TB in African counties (case study, Nairobi Kenya) <i>Reviewer: Diana Marangu</i>	Sophy Badia
(P307) Integrating Quality Improvement to Increase Tuberculosis Active Case Finding in Giribe Dispensary <i>Reviewer: Evans Amukoye</i>	Josephine Mbinya Ngangi
(P308) Recruitment of a TB and TB/HIV Co-infected participants in a cohort study <i>Reviewer: Diana Marangu</i>	Paul Waiganjo
(P309) Scaling up Tb case finding by use of presumptive Tb register - a case in Tisinye health centre, Migori county <i>Reviewer: Jeremiah Chakaya</i>	George Obonyo
(P310) Challenges of unsupervised sputum samples collection for Mycobacterium tuberculosis analysis <i>Reviewer: Joy Eze</i>	Martha Njoroge
(P311) Sputum Culture Conversion rates in relation to HIV status after 6 months of Tuberculosis treatment in Nairobi Kenya <i>Reviewer: Diana Marangu</i>	Dorcas Ihuthia
(P312) Sputum quality as a predictor of bacteriologically-confirmed TB by smear and culture in Nairobi county <i>Reviewer: Joy Eze</i>	Robu Chacha
(P313) Automation of active TB case finding in Electronic Medical Record in increasing TB case identification in Matata hospital, Homabay County <i>Reviewer: Jeremiah Chakaya</i>	Korir Brian
(P314) Role of Pulmonary Rehabilitation on the Health-Related Quality of Life in People affected with Post TB Lung Diseases in Tanzania <i>Reviewer: Jeremiah Chakaya</i>	Kassim Msaji
(P315) Improving TB case finding through strengthening the use of Chest X-rays as a TB screening tool for presumptive cases. A case of Kamiti prison hospital, Nairobi <i>Reviewer: Lorraine Mugambi</i>	Peninah Makena Michukil
(P316) Optimization of smear microscopy to enhance afb detection. A case study of Tisinye health centre. Migori County <i>Reviewer: Diana Marangu</i>	Evans Ondieki





Programme

13:45-15:15	Plenary 5: Closing the screening gap for respiratory diseases Chairs: Obianuju Ozoh (Nigeria) & Heather Zar (SA)	Venue: Johari 2-A
13:45-14:15	Lung cancer screening in limited resource settings	Patricia Rivera (USA)
14:15-14:45	Can early lung function screening reduce future morbidity and mortality?	Diane Gray (South Africa)
14:45-15:15	The Modern Thoracic Surgeon is a VATS Surgeon	Ivan Schewitz (South Africa)
15:15-15:30	TEA/COFFEE	
15:30-17:00	Adult Track 4: Interstitial and Environmental Lung Disease in Africa: what do we really know? Chairs: George Nyale (Kenya) & Bertrand Mbatchou (Cameroon)	Venue: Johari
15:30-16:00	ILD- in Africa: where is the data?	Jumaa Bwika (Kenya)
16:00-16:30	Sarcoidosis in Africa	Jeremiah Chakaya (Kenya)
	<u>Oral Abstract Presentations:</u>	
16:30-16:40	Diversity of indoor fungi and associated respiratory disorders in Nairobi and Busia Counties, Kenya	Olga Mashedi (Kenya)
16:40-16:50	Interventions to reduce outdoor air pollution and its impact on asthma outcome: A systematic review	Sbekezelo Hlophe (South Africa)
16:50-17:00	Prevalence and factors associated with smoking in Uganda	Joanita Nalunjogi (Uganda)
15:30-17:00	Paediatric Track 4: Chronic lung disease in children Chairs: Justus Simba (Kenya) & Norbertta Makumbe Washaya (Zimbabwe)	Venue: Baraza 2&3
15:30-16:00	Bronchiectasis in children	Adaeze Ayuk (Nigeria)
16:00-16:30	Asthma monitoring in children: which test?	Marielle Pijnenburg (Netherlands)
16:30-17:00	Pulmonary disease in sickle cell disease	Sandra Kwarteng Owusu (Ghana)
15:00-17:00	Thoracic Surgery Track 5: Infections and Surgery Chairs: I. Schewitz (South Africa) & N. Khan (Germany)	Venue: Forodhahi
15:00-15:30	Management of Hydatid Disease in the Thorax	Souheil Boubia (Morocco)
15:30-16:00	Peri-mammary VATS for Pleuraempyema	Norberto Santana Rodriguez (UAE)
16:00-16:30	Abnormal foreign Body extraction	Yasser Elsayed (Egypt)
16:30-17:00	Uniportal thoracoscopic decortication: Utility of the SAFE approach	Hussein Elkhayat (Egypt)
17:15-18:30	Paediatric Pulmonology Curriculum Meeting	Norbertta Makumbe Washaya (APFP)
19:00-22:00	Gala Dinner	
SATURDAY 10 JUNE 2023		
08:30-17:30	Post-congress Workshops	Venue: Baraza 1
	Skills Building Workshop 5 - Air Quality Monitoring	Sean Semple (UK)
08:30-09:40	Adult Track 5: Tuberculosis in Africa: back to the future Chairs: Jeremiah Chakaya (Kenya) Lorraine Mugambi	Venue: Johari
08:30-09:00	Taking advantage of advances in TB diagnosis and treatment to tame TB in Africa	Kenneth Musisi
09:00-09:30	Post TB lung disease: Tool kit for diagnosis and management	Brian Allwood (South Africa)
	<u>Oral Abstract Presentations:</u>	
09:30-09:40	Cytokine profile of a TB and TB/HIV co-infected cohort in Kenya	Asiko Ongaya (Kenya)





Programme

08:30-10:10	Paediatric Track 5: Lung disease in children Chairs: Anne Irungu (Kenya) & Diana Marangu (Kenya)	Venue: Baraza 2
08:30-09:00	Childhood pneumonia: impact of pneumococcal conjugate vaccine	Heather Zar (South Africa)
09:00-09:30	Covid-19 in African children	Moherndran Archary (South Africa)
09:30-10:00	New developments in bronchopulmonary dysplasia	Marielle Pijnenburg (Netherlands)
	<u>Oral Abstract Presentations:</u>	
10:00-10:10	Delay in seeking healthcare for children less than five years with severe pneumonia in Mulago tertiary care hospital, Uganda	Phiona Ekyaruhanga (Uganda)
08:00-10:00	Thoracic Surgery Track 6: VATS Segmentectomies: A Master Class Chairs: H. Elkhayat (Egypt) & S. Boubia (Morocco)	Venue: Forodhahi
08:00-08:20	VATS Segmentectomy	Ayman ALMasri (Egypt)
08:20-08:40	VATS Segmentectomy	Husam Enaami (Libya & Germany)
08:40-09:00	VATS Segmentectomy	Ali Zamir Khan (India and UK)
09:00-09:20	VATS Segmentectomy	Stamenovic, Davor (Germany)
09:20-09:40	VATS Segmentectomy	Hauke Winter (Germany) [Virtual]
09:40-10:00	Panel Discussion	
10:00-10:30	TEA/COFFEE	
10:30-12:30	Plenary 6: The future for tuberculosis and lung health Chairs: Evans Amukoye (Kenya) & Andrew Owuor	Venue: Johari 2-A
10:30-11:00	New advances in prevention and treatment of Pediatric TB	Diana Marangu (Kenya)
11:00-11:30	When TB cure is not enough: managing Post TB Chronic Lung Disease	Brian Allwood (South Africa)
11:30-12:00	Integrating TB care into respiratory practice: why and how?	Jeremiah Chakaya (Kenya)
12:00-12:30	The role of surgery in TB management	Souheil Boubia (Morocco)
12:30-12:40	Closing Ceremony - Comminuque - Anne	Venue: Johari 2-A
12:45-13:00	Vote of thanks and announcement of next congress	Obianuju Ozoh (Nigeria)



Speaker Bios



**Oral Presentations
(Book of Abstracts)**



**Poster Presentations
(Book of Abstracts)**



Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study

Making the right choice of macrolide when treating severe CAP¹

NEW EVIDENCE



A matched comparator study was conducted to determine differential efficacy between macrolides¹

STUDY INCLUDED:


1 174 patients ≥ 18 years old with severe CAP¹

4 treatment groups:¹

- Clarithromycin + one β-lactam
- Azithromycin + one β-lactam
- Respiratory fluoroquinolone (moxifloxacin or levofloxacin alone)
- β-lactam monotherapy

RESULTS:

Mortality was significantly higher in the azithromycin and respiratory fluoroquinolone groups vs. the clarithromycin group¹



Adapted from Kyriazopoulou E, et al. 2020¹

CONCLUSION

The addition of clarithromycin (e.g. KLACID[®]), rather than azithromycin to one β-lactam, demonstrates superior survival benefit vs. azithromycin in combination with one β-lactam, and respiratory fluoroquinolone monotherapy.¹

Reference: 1. Kyriazopoulou E, Sniapida D, Halatzis S, et al. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study. *Int J Antimicrob Agents* 2020;55(1):105836.

KLACID[®] P125 Granules for Suspension. Granules are supplied in 50 ml bottles. After suspension, each 5 ml of KLACID[®] P125 contains 125 mg clarithromycin. PHARMACOLOGICAL CLASSIFICATION: A 20.1.1 - Medium and broad-spectrum antibiotics. Reg. No.: 29/20.1.1/0205. KLACID[®] P250 Granules for Suspension. Granules are supplied in 50 or 100 ml bottles. After suspension, each 5 ml of KLACID[®] P250 contains 250 mg clarithromycin. PHARMACOLOGICAL CLASSIFICATION: A 20.1.1 Medium and broad-spectrum antibiotics. Reg. No.: 29/20.1.1/0190. KLACID[®] XL Modified release tablets. KLACID[®] XL is supplied in blister packs of 5 and 10 tablets. Each tablet contains 500 mg clarithromycin. PHARMACOLOGICAL CLASSIFICATION: A 20.1.1 - Medium and broad-spectrum antibiotics. Reg. No.: 31/20.1.1/0379. KLACID[®] 1X Lyophilised Powder for Injection. KLACID[®] 1X Lyophilised Powder for Injection is supplied in clear glass vials with a capacity of 15 ml. Each vial contains 500 mg clarithromycin. PHARMACOLOGICAL CLASSIFICATION: A 20.1.1 Medium and broad-spectrum antibiotics. Reg. No.: 29/20.1.1/0204. Abbott Laboratories S.A. (Pty) Ltd. Reg. No.: 1940/0140/07. Abbott Place, 219 Golf Club Terrace, Constantia Kloof, 7708. Tel: (071) 858 2000. Publication date: May 2020. Promotional review number: SAF2152252.



MORE THAN 30 YEARS OF GLOBAL FLU PREVENTION¹





Thank You To All Our Sponsors

On behalf of the PATS & ReSoK organising committee, we would like to thank the following companies for their contribution toward the success of the congress.



Societies





Notes





Notes

A series of 28 horizontal lines for writing notes.





Notes





MICRO LABS LIMITED

In the treatment of Seasonal & Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria, Prophylaxis and treatment of Asthma.

Montral

Montelukast 10mg + Levocetirizine 5mg

SYNERGISM AT ITS BEST



In the Jungle...
Speed Matters.

In Infection Management...

Dose Matters.

Levobact-750

Levofloxacin Hemihydrate Tablets 750 mg



Indicated in the treatment of Nosocomial Pneumonia, Acute Bacterial Sinusitis, Complicated UTI, Acute Pyelonephritis, Typhoid, and Complicated SSSI.





Programme Sponsored By



CONGRESS ORGANISER

Diné Poulton | +27 82 773 1851 | dine@londocor.co.za

